Skip to content

Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advanced ovarian cancer (CISCON)

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514711-99-00
Enrollment
40
Registered
2024-06-13
Start date
2022-05-02
Completion date
Unknown
Last updated
2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FIGO stage III high grade serous ovarian cancer, peritoneal cancer, or fallopian tube carcinoma

Brief summary

intratumoral Pt concentration at the end of perfusion after 90 min (in ng/mg wet tissue)

Detailed description

Toxicity evaluation (CTCAE 5.0), Pt concentration in normal tissue (in ng/mg wet tissue), Pt concentration in tumor tissue after 30 min and 60 min of perfusion (in ng/mg wet tissue), Concentration versus time curve and AUC of intra-peritoneal Pt during perfusion, Cmax, tmax, terminal t ½ in perfusate, clearance from perfusate at the end of perfusion, Recurrence-free survival (RFS) and Overall survival (OS)

Interventions

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
intratumoral Pt concentration at the end of perfusion after 90 min (in ng/mg wet tissue)

Secondary

MeasureTime frame
Toxicity evaluation (CTCAE 5.0), Pt concentration in normal tissue (in ng/mg wet tissue), Pt concentration in tumor tissue after 30 min and 60 min of perfusion (in ng/mg wet tissue), Concentration versus time curve and AUC of intra-peritoneal Pt during perfusion, Cmax, tmax, terminal t ½ in perfusate, clearance from perfusate at the end of perfusion, Recurrence-free survival (RFS) and Overall survival (OS)

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026